Skip to content
Open access

mTORC1 activation induces B7-H3-dependent metabolic reprogramming in renal cell carcinoma (RCC)

Jul 2026 · Oncogene · Vol 45, pp. 3525 - 3540 · 0 citations · 84 references
Medicine

TL;DR

Findings identify B7-H3 as a functional driver of Tsc2-mediated ChRCC and a promising therapeutic target in TSC-associated renal tumors.

Abstract

Renal cell carcinoma (RCC) affects over 435,000 people worldwide each year and remains a significant cause of cancer mortality. Aberrant activation of pathways such as mTORC1 is frequently observed in RCC, yet the mechanisms by which mTORC1 contributes to tumor development remain poorly understood. The lack of suitable animal models has limited progress in uncovering these mechanisms and advancing targeted treatments. Here, we performed single-cell transcriptomic, proteomic, and metabolomic profiling of kidneys from mice with embryonic Tsc2 deletion at E17.5, which revealed a distinct tumor cell population characterized by intercalated cell signatures, co-expression of Foxi1 and Rhcg, and hyperactivated mTORC1. These lesions closely resemble human chromophobe renal cell carcinoma (ChRCC), a subtype of RCC. The tumors show marked upregulation of the immune checkpoint molecule B7-H3. Mechanistically, the transcription factor NRF1 is elevated in Tsc2-deficient lesions and drives B7-H3 expression in tumor cells. In human specimens, B7-H3 is broadly expressed in both classical and sarcomatoid ChRCC and correlates with hallmark markers FOXI1, MUC2, and HEPACAM2. Strikingly, B7-H3 deletion in mice suppresses Tsc2 loss-driven cystic and tumor formation, restores amino acid metabolism, and attenuates aminoacyl-tRNA biosynthesis and proteasome activity. Collectively, these findings identify B7-H3 as a functional driver of Tsc2-mediated ChRCC and a promising therapeutic target in TSC-associated renal tumors.

Read PDF

Similar papers

Aug 2026

Epigenetic inactivation of COL4A4 orchestrates JAK2/STAT3-driven progression and microenvironment reprogramming in renal cell carcinoma.

COL4A4 acts as a methylation-silenced RCC tumor suppressor that negatively modulates JAK2/STAT3 signaling and correlates with TME features, representing a potential epigenetic therapeutic target.

Hanxi Zhou, Xiong Tian, Zhenyu Yang et al. · 0 citations
Open access Sep 2026

Promoter Hypermethylation-Driven NPHS2 Silencing Promotes Immune Escape and Sunitinib Resistance in Clear Cell Renal Cell Carcinoma

Objective: Renal cell carcinoma is a common malignancy of the urinary system. In this study, we analyzed a public clear cell renal cell carcinoma (ccRCC) dataset and identified Nephrosis 2, idiopathic, steroid-resistant (NPHS2) as a candidate gene to investigate whether epigenetic dysregulation of NPHS2 is associated w...

Shang-Jian Li, Qi-Peng Han, Xin-Ying Sun et al. · 0 citations
Open access Sep 2026

Combined Loss of VHL and TSC1 Drives Clear Cell Renal Cell Carcinoma with Metabolic and Redox Reprogramming that Creates an NRF2 Dependency

Cancer genomics studies have implicated combined loss of VHL and TSC1 as sufficient to initiate clear cell renal cell carcinoma (ccRCC) in humans. Here, we engineered a mouse model with kidney-specific deletion of Vhl and Tsc1. VhlF/FTsc1F/FKsp-Cre+mice developed multifocal renal cell carcinomas starting at 7 weeks of...

Jia-Ning Xu, Xiao-Qing Cheng, O. A. Aboud et al. · 0 citations
Sep 2026

Context-dependent effects of MIR100HG on tumorigenic phenotypes and p38/MAPK–AKT signaling in hepatocellular carcinoma

The findings suggest that the effects of MIR100HG on oncogenic signaling are highly dependent on the cellular oxygenation context and that hypoxia reshapes the downstream signaling consequences of MIR100HG expression in HCC cells.

E. Tokay, Sevin Avsar Koc, Aylin Turkoglu Dulger et al. · 0 citations
Open access Aug 2026

Crosstalk Between mTOR and NF-κB Signaling Pathways in Clear Cell Renal Cell Carcinoma

Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive type of renal cell carcinoma (RCC), representing approximately 80% of cases globally. Despite improved diagnosis and therapy, treatment of aggressive or metastatic ccRCC remains challenging due to acquisition of primary or secondary resistance. A...

Melanie Glueck, Alexandra Lucaciu, Sumedha Inukollu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.